Evidence map›Paper›PMID 41723637›Full record

ReviewImmunoHorizons2026

Trained immunity: new paradigm in the immunological memory of cardiovascular disease.

Emma Hope, Azuah L Gonzalez, Lola S Norman, Hunter C Smith, Jean W Wassenaar, Kasey C Vickers, Jonathan D Brown, Amanda C Doran

Abstract readReview
In one paragraph

Review in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emma HopeDepartment of Pathology, Microbiology, & Immunology, Vanderbilt University, Nashville, TN, United States.
Azuah L GonzalezDepartment of Pathology, Microbiology, & Immunology, Vanderbilt University, Nashville, TN, United States.
Lola S NormanDepartment of Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, United States.
Hunter C SmithDepartment of Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, United States.
Jean W WassenaarDepartment of Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, United States.
Kasey C VickersDepartment of Pathology, Microbiology, & Immunology, Vanderbilt University, Nashville, TN, United States.
Jonathan D BrownDepartment of Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, United States.
Amanda C DoranDepartment of Pathology, Microbiology, & Immunology, Vanderbilt University, Nashville, TN, United States.

Funding

Non-coding RNA & Bioinformatics CoreP01HL116263 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DAVIES, SEAN STEPHEN · 2014 to 2025
$24.7M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Critical Mediators of Inflammation Resolution and Immune Memory in AtherosclerosisR01HL159487 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DORAN, AMANDA C · 2021 to 2025
$3.2M
Hypertension-associated Trained Immunity in Myeloid Cells is a Determinant of AtherosclerosisR01HL174961 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JONATHAN David BROWN, AMANDA C DORAN · 2025 to 2026
$1.5M
CaMK4 as a Critical Mediator of Inflammation Resolution and Trained ImmunityF31HL172670 · NHLBI · VANDERBILT UNIVERSITY · PI GONZALEZ, AZUAH LUCRECIA · 2024 to 2025
$69k
American Heart Association-American Stroke Association AHA_24CDA1278132NHLBI NIH HHS F31 HL172670NHLBI NIH HHS P01 HL116263NHLBI NIH HHS R01 HL159487NHLBI NIH HHS R01 HL174961NIGMS NIH HHS T32 GM152284NIH HHS T32 GM152284
6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide, despite significant progress in identifying and managing traditional risk factors such as hyperlipidemia, hypertension, and diabetes. While targeted therapies addressing these factors reduce the risk of primary and secondary cardiac events, a substantial "residual risk" persists even after successful clinical intervention. This residual risk has prompted renewed interest in understanding the long-term biological effects of cardiovascular risk factors, particularly through the lens of chronic inflammation. Recent advances highlight a pivotal role for trained immunity-a form of innate immune memory driven by epigenetic and metabolic reprogramming-in driving this inflammation. Unlike adaptive immune memory, trained immunity occurs in innate immune cells and enhances their responsiveness to subsequent, unrelated stimuli. Emerging evidence suggests that various cardiovascular risk states, including hypercholesterolemia, obesity, and diabetes, can induce trained immunity, leading to heightened inflammatory tone that persists over time. Cardiac macrophages, as central mediators of tissue homeostasis and inflammation in the heart, are increasingly recognized as critical targets of this phenomenon. In this review, we explore how established cardiovascular risk factors can induce trained immunity on cardiac macrophages and examine the implications for disease progression, myocardial remodeling, and post-injury repair. Finally, we discuss emerging therapeutic strategies aimed at modulating trained immunity to reduce residual cardiovascular risk, offering a new frontier in the prevention and treatment of CVD.

Indexed as

Cardiovascular DiseasesImmunologic MemoryTrained ImmunityAnimalsHumansImmunity, InnateInflammationMacrophagesRisk Factorsinflammationmemorymonocyte/macrophages

Identifiers

PMID41723637
PMCPMC12925321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.